Streetbeat News

Regulatory

ZENA

ZenaTech's subsidiary, ZenaDrone, has acquired a US design patent for a drone design used in its ZenaDrone 1000 product. This patent could enhance ZenaTech's competitive edge in the drone market.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 11:33 am

PBM

Psyence Biomedical has chosen Empax Center as the second trial site for its Phase 2b trial of nature-derived psilocybin, aimed at treating adjustment disorder in palliative care.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 11:33 am

TSCO

Tractor Supply has signed a definitive agreement to acquire Allivet, an online pet pharmacy, in an all-cash transaction. The acquisition aims to provide a low-cost pet pharmacy solution for its members. The deal is expected to close in the first quarter of 2025, pending regulatory approvals.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 11:32 am

LYFT

TSLA

UBER

Uber and Lyft shares fell in pre-market trading after Tesla CEO Elon Musk announced the testing of Tesla's new Cybercab in San Francisco. The ride-hailing feature is currently available for Tesla employees, with plans to expand to the public in California and Texas next year. This development has impacted Uber and Lyft's stock performance as Tesla's entry into the ride-hailing market becomes more tangible.

Portfolio Pulse from Pooja Rajkumari

October 24, 2024 | 11:03 am

CYBN

Cybin Inc. has secured a US patent for its CYB005 phenethylamines program, focusing on non-hallucinogenic treatments for CNS disorders. This patent supports Cybin's innovative development beyond its clinical tryptamine programs. The company is also advancing its CYB003 and CYB004 programs, with significant upcoming trials and results expected in 2024.

Portfolio Pulse from Vandana Singh

October 24, 2024 | 11:01 am

CYBN

Cybin has announced the grant of its first U.S. Composition of Matter Patent for its CYB005 phenethylamines program, marking a significant milestone for the company.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 11:00 am

MRK

Merck announced that the European Commission has approved two new indications for KEYTRUDA, its anti-PD-1 therapy, in gynecologic cancers. This includes the first EU approval for KEYTRUDA combined with chemotherapy for patients with primary advanced or recurrent endometrial carcinoma, regardless of mismatch repair status.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 10:47 am

HALO

Halozyme Therapeutics announced that the European Patent Office's decision to revoke a Janssen co-formulation patent for DARZALEX will not impact its US or European royalty revenues from DARZALEX FASPRO and SC through 2032. The company reaffirmed its guidance.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 10:33 am

MRK

The CDC has recommended Merck's CAPVAXIVE vaccine for adults aged 50 and older, expanding protection against invasive pneumococcal disease. This recommendation lowers the age for vaccination from 65 to 50 years. CAPVAXIVE covers 84% of disease-causing serotypes, compared to 52% by PCV20.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 6:50 am

PHAR

Pharming Group reaffirms its 2024 revenue guidance of $280M-$295M, indicating 14% to 20% growth. The company plans to increase revenues through patient conversion to Joenja® therapy, expand leniolisib's market presence, and pursue regulatory approvals globally. They are also exploring acquisitions in rare diseases.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 5:42 am